Drug facts
MoleculeDonepezil (Aricept)
Generics already compete: 19 makers on the market. 39 A-rated products from 19 makers substitute at the counter.
Aricept was first approved by the FDA on 11/25/1996 under NDA 020690; the application holder is Eisai Inc.
The latest NADAC for DONEPEZIL HCL 10 MG TABLET is $0.05 per unit (as of 10/28/2026).
Holder Eisai IncApplication NDA 020690Approved 11/25/1996
01Patents and exclusivity
When competition can legally begin. A generic can launch once both exclusivity and the last listed patent expire, unless a court or settlement says otherwise.
- Latest patent
- No NDA 020690 patent listed in the Orange Book Orange Book
- Later patents, other products
- Adlarity 08/11/2038; Aricept (NDA 022568) 10/04/2026 Orange Book
02Competition
- Generics
- 19 generic makers Orange Book
- First generic approved
- 12/11/2009 Orange Book
Every listingEach listing and maker behind the generics count.
Price erosionHow NADAC moves as generics enter.
PrescribersWho prescribes it, from Medicare data.
Available in the full Donepezil profile.See what is included
03Supply and price
- FDA drug shortage
- ClearNot on the current shortage list FDA shortages
- NADAC
- $0.05 per unitDONEPEZIL HCL 10 MG TABLET, mid-priced of 3 strengths, as of 10/28/2026 CMS NADAC
- Latest recall
- 01/26/2022Class II, Donepezil Hydrochloride, Cardinal Healthcare FDA enforcement
04Product
- Application holder
- Eisai Inc Orange Book
- Application
- NDA 020690 Orange Book
- First approved
- 11/25/1996 Orange Book
- Dosage forms
- tablet; tablet, orally disintegrating
- Routes
- oral
Sources: FDA Orange Book, FDA Purple Book, FDA drug shortages, FDA enforcement reports and CMS NADAC, read through QOPE. Not medical or legal advice.